Synthetic RIG-I agonist-mediated cancer immunotherapy synergizes with MAP kinase inhibition against BRAF-mutated melanoma.
Molecular therapy. Nucleic acids
View this publicationMolecular therapy. Nucleic acids
View this publicationNature chemical biology
View this publicationPublication categories: Top publication
Nature
View this publicationPloS one
View this publicationPublication categories: Top publication
Nature biotechnology
View this publicationScience (New York, N.Y.)
View this publication